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A B S T R A C T
Purpose
Current immunohistochemical (IHC)-based definitions of luminal A and B breast cancers are
imperfect when compared with multigene expression-based assays. In this study, we sought to
improve the IHC subtyping by examining the pathologic and gene expression characteristics of
genomically defined luminal A and B subtypes.
Patients and Methods
Gene expression and pathologic features were collected from primary tumors across five independent
cohorts: British Columbia Cancer Agency (BCCA) tamoxifen-treated only, Grupo Español de Investi-
gación en Cáncer de Mama 9906 trial, BCCA no systemic treatment cohort, PAM50 microarray training
data set, and a combined publicly available microarray data set. Optimal cutoffs of percentage of
progesterone receptor (PR) –positive tumor cells to predict survival were derived and independently
tested. Multivariable Cox models were used to test the prognostic significance.
Results
Clinicopathologic comparisons among luminal A and B subtypes consistently identified higher
rates of PR positivity, human epidermal growth factor receptor 2 (HER2) negativity, and
histologic grade 1 in luminal A tumors. Quantitative PR gene and protein expression were also
found to be significantly higher in luminal A tumors. An empiric cutoff of more than 20% of
PR-positive tumor cells was statistically chosen and proved significant for predicting survival
differences within IHC-defined luminal A tumors independently of endocrine therapy admin-
istration. Finally, no additional prognostic value within hormonal receptor (HR) –positive/HER2-
negative disease was observed with the use of the IHC4 score when intrinsic IHC-based
subtypes were used that included the more than 20% PR-positive tumor cells and vice versa.
Conclusion
Semiquantitative IHC expression of PR adds prognostic value within the current IHC-based
luminal A definition by improving the identification of good outcome breast cancers. The new
proposed IHC-based definition of luminal A tumors is HR positive/HER2 negative/Ki-67 less
than 14%, and PR more than 20%.
J Clin Oncol 31:203-209. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Hormonal receptor (HR) –positive breast cancer
is a clinically and biologically heterogeneous
entity.1-3 Studies based on gene expression profil-
ing have identified at least two major groups of
HR-positive tumors, known as the luminal A and
B intrinsic subtypes of breast cancer. These two
molecular entities have shown significant differ-
ences in baseline prognosis and sensitivity to cy-
totoxic therapies.4-6
Currently, a gene expression–based assay
known as the PAM50 subtype predictor identifies
the intrinsic molecular subtypes of breast cancer and
provides a risk of relapse (ROR) score in a fashion
similar to the Oncotype DX (Genomic Health, Red-
wood City, CA) recurrence score (RS).4-6 These two
assays provide valuable and independent prognostic
information beyond standard clinicopathologic
variables. However, standardized gene expression–
based tests are not readily available in most of the
world as a result of cost, assay turnaround times, and
other logistic issues. Thus surrogate definitions of
the intrinsic subtypes and/or risk of relapse groups
developed using routine pathology and clinical pa-
rameters could be of great practical value.7,8
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We have previously reported an immunohistochemical (IHC)-
based surrogate definition of the luminal A (IHC-luminal A) and
luminal B/human epidermal growth factor receptor 2 (HER2)
-negative (IHC-luminal B/HER2-negative) subtypes based on the
quantitative expression of the proliferation-related marker Ki-67
within HR-positive/HER2-negative disease.9 This definition has now
been adopted by the 2011 St Gallen Expert Consensus Panel Recom-
mendation Guidelines for the systemic treatment of early breast can-
cer,10 which recommend adjuvant endocrine therapy alone for
patients with IHC-luminal A tumors and the addition of chemother-
apy for patients with IHC-luminal B/HER2-negative tumors. Here we
further refine the IHC-based definition of luminal A and B through
the use of quantitative progesterone receptor (PR) expression.
PATIENTS AND METHODS
Patients, Samples, and Clinical Data
Multiple different and independent data sets were used to assess the
significance of PR IHC results. Gene expression and/or clinicopathologic
features were evaluated across five different data sets: (1) a combined genomic
data set of nine publicly available microarray cohorts (GSE18229, GSE18864,
GSE22219, GSE25066, GSE2990, GSE4922, GSE7390, GSE7849, and
NKI295), (2) the PAM50 microarray-based subtype predictor training data set
(PAM50-training, GSE10886),5 (3) a British Columbia Cancer Agency
(BCCA) tamoxifen-treated cohort (BCCA-tamoxifen),6 (4) the Grupo Espa-
ñol de Investigación en Cáncer de Mama (GEICAM) 9906 trial,11 and (5) the
BCCA no adjuvant systemic therapy (AST) cohort (BCCA-no AST).9 A de-
tailed CONSORT diagram can be found in Appendix Table A1 (online only).
All patients from the BCCA-tamoxifen cohort6 had early-stage HR-
positive disease and received adjuvant treatment with tamoxifen only. In the
GEICAM 9906 phase III trial cohort,11 patients with node-positive disease
were randomly assigned to adjuvant fluorouracil, epirubicin, and cyclophos-
phamide versus fluorouracil, epirubicin, and cyclophosphamide followed by
weekly paclitaxel, and patients with HR-positive disease subsequently received
adjuvant endocrine therapy. The BCCA-no AST cohort9 includes “clinically
low risk” patients with primary breast cancer diagnosed between 1986 and
1992 who did not receive adjuvant systemic therapy. Characteristics of both
BCCA cohorts and the GEICAM 9906 cohort have been previously de-
scribed.6,9,11 From the PAM50-training cohort, we performed global and
single gene expression analyses using only the prototypical samples of the
luminal A and B subtype. Finally, the combined microarray data set included
nine publicly available data sets of primary breast cancers with annotated
clinicopathologic data.
PAM50 Intrinsic Subtyping
All tumors were assigned an intrinsic molecular subtypes of breast cancer
(luminal A, luminal B, HER2-enriched, and basal-like) and the normal-like
group using the PAM50 subtype predictor.5,6 In the BCCA-tamoxifen and
GEICAM 9906 cohorts,11 PAM50 was determined using a quantitative
reverse-transcriptase polymerase chain reaction–based assay.5,6 In the
GEICAM 9906 cohort, we evaluated the PAM50 ROR score based on subtype
and proliferation (ROR-P) as previously described for the BCCA-tamoxifen
cohort.6 In each individual publicly available microarray cohort, we applied
the PAM50 microarray-based algorithm5 after data set to data set normaliza-
tion based on median gene centering within each data set.
IHC-based subtyping was determined using the following definitions
adopted by the 2011 St Gallen Consensus Panel10: IHC-luminal A (HR posi-
tive/HER2 negative/Ki-67  14%), IHC-luminal B/HER2-negative (HR pos-
itive/HER2 negative/Ki-67  14%), IHC-luminal B/HER2-positive (HR
positive/HER2 positive), IHC-HER2 (HR negative/HER2 positive), and
triple-negative (HR negative/HER2 negative). Detailed IHC-based protocols
for estrogen receptor (ER), PR, HER2, and Ki-67 determinations have been
previously described6,9,11,12 and are summarized in Appendix Table A2 (on-
line only). All IHC-based tissue microarray images of both BCCA cohorts can
be obtained via the Genetic Pathology Evaluation Centre TMA Viewer.13
IHC4 Score
A version of the IHC4 score was evaluated in HER2-negative disease
using the reported formula.8 However, instead of using the H-score reported
in Cuzick et al8 for estimating the semiquantitative expression of ER, we
determined a general intensity score value of 0 to 3 and multiplied this value by
the percentage of ER-positive tumor cells for a final ER score of 0 to 300.
Statistical Analysis
Significant differences in clinicopathologic features between groups were
evaluated using either the 2 test or the t test. Estimates of survival were from
the Kaplan-Meier curves and tests of differences by the log-rank test. Univar-
iate and multivariate Cox models were used to test the independent prognostic
significance of each variable. Over-represented biologic processes were identi-
fied with Expression Analysis Systematic Explorer (EASE). 14
To identify an optimal cutoff of percentage of PR-positive tumor cells
within IHC-luminal A tumors, we applied the penalized spline method on
multivariable Cox regression analysis in the BCCA-tamoxifen cohort6 (train-
ing data set), and the optimal cutoff to predict distant relapse–free survival
(DRFS) was independently tested in the GEICAM 990611 and BCCA-no
AST9 cohorts.
To test the contribution of the IHC4 score, IHC-based subtyping and the
PAM50 ROR-P score, all of these variables were tested in a prognostic model
within HR-positive/HER2-negative disease. Here we estimated the log likeli-
hood ratio statistic of each variable as an addition to a model containing the
following clinical variables in the GEICAM 9906 cohort11: treatment arm,
histologic grade, tumor stage, nodal status, and age. Finally, we estimated the
log likelihood ratio statistic of each variable as an addition to a model contain-
ing clinical variables and one or two of the three variables being evaluated
(IHC4 score, intrinsic IHC-based subtyping, and PAM50 ROR-P).
RESULTS
Gene and Protein Expression Differences Between
Luminal A and B Tumors
To identify global and single gene expression differences, we
performed a two-class significance analysis of microarrays between
prototypical luminal A and B tumors from the PAM50-training co-
hort.5 A total of 1,539 genes (348 upregulated and 1,191 downregu-
lated) were found differentially expressed (false discovery rate  1%)
between both subtypes (Appendix Fig A1, online only; Data Supple-
ment). The upregulated gene list in luminal A tumors was found
enriched for genes involved in cell differentiation (eg, Kruppel-like
factor 4 and jun proto-oncogene) and cell adhesion (eg, vinculin and
collagen, type XVI, 1) biologic processes. Conversely, the downregu-
lated gene list in luminal A tumors (ie, genes highly expressed in
luminal B tumors) was found enriched for genes involved in immune
response (eg, interleukin 2 receptor  and CD86) and cell-cycle (eg,
cyclin B1 and RAD51) biologic processes, which is indicative of the
faster proliferation rates known to be part of luminal B tumors.
Among the relatively upregulated genes in luminal A tumors was
the progesterone receptor gene (PGR), but not the estrogen receptor
gene (ESR1). To further explore these findings, we evaluated the
mRNA expression of PGR and ESR1 in two independent studies in
which PAM50 was performed using the quantitative reverse-
transcriptase polymerase chain reaction platform (GEICAM 990611
and BCCA-tamoxifen6) and confirmed that PGR, but not ESR1, was
found significantly upregulated in luminal A tumors compared with
luminal B tumors (Figs 1A and 1B; P  .001, t test). Interestingly, PGR
was found only weakly correlated (Pearson correlation coefficient 
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0.19) with the expression of the Ki-67 gene MKI67, indicating that
these two genes may provide different biologic information.
The mRNA expression-based data suggested that semiquan-
titative scoring of the PR protein, but not ER protein, might help
discriminate the genomically defined luminal A from B tumors. To
further explore this hypothesis, we compared the percentage of
PR-positive and ER-positive tumor cells as assessed by IHC, among
luminal A and B tumors in the GEICAM 9906 cohort,11 and
observed that only the percentage of PR-positive cells can discrim-
inate luminal A from B tumors (Figs 1C and 1D). However, it is
important to note that considerable overlap was observed. Finally,
PR protein expression was also weakly anticorrelated with Ki-67
protein expression (r  0.20).
Clinicopathologic Features of Luminal
A and B Tumors
To identify clinicopathologic differences among the genomi-
cally defined luminal A and B tumors, we evaluated the clinico-
pathologic features of 2,257 patients with luminal A or B primary
breast cancer. Across three independent cohorts (Table 1), luminal
A tumors showed significantly higher rates of PR positivity, HER2
negativity, histologic grade 1, and tumor stage T0-T1 compared
with luminal B tumors. No significant differences in ER status were
observed, with the vast majority (92% to 96%) of luminal A and B
tumors being ER positive.
IHC-Based Versus PAM50 Subtype Definitions
Current IHC-based definitions of luminal A and B subtypes are
imperfect when compared with multigene expression-based assays.5
To further illustrate this, we evaluated the distribution of the
IHC-based definitions within luminal A and B tumors in the BCCA-
tamoxifen6 and the GEICAM 9906 cohorts.11 As expected, whereas a
large majority (81% to 85%) of luminal A tumors were identified as
IHC-luminal A, 35% to 52% of luminal B tumors were also identified
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Fig 1. Expression of the hormonal receptors in the Grupo Español de Investigación en Cáncer de Mama 9906 data set. (A) Estrogen receptor (ER) gene (ESR1) and
(B) progesterone receptor (PR) gene (PGR) as assayed using quantitative reverse-transcriptase polymerase chain reaction expression in luminal A and B tumors. Density
plots based on the percentage of (C) ER-positive and (D) PR-positive tumor cells as assessed by immunohistochemistry.
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Finally, we explored the survival of the luminal A and B subtypes
within the IHC-based luminal A and IHC-luminal B/HER2-negative
tumors in the BCCA-tamoxifen cohort6 (Appendix Table A3, online
only). In both cases, luminal A tumors showed a significantly better
DRFS outcome than non–luminal A tumors. In multivariable Cox
model survival analyses adjusted for histologic grade, age at diagnosis,
nodal positivity, and tumor size, the hazard ratio for DRFS in PAM50
luminal A tumors compared with PAM50 non–luminal A was 0.642
within IHC-luminal A tumors (95% CI, 0.422 to 0.975, P  .038) and
0.582 within IHC-luminal B/HER2-negative tumors (95% CI, 0.323
to 1.047, P  .071).
Survival Outcomes Based on the Percentage of
PR-Positive Cells
These data suggested that (1) further improvements in the IHC-
luminal A definition is needed because many PAM50-defined luminal
B tumors are erroneously identified as IHC-luminal A and (2) quan-
titative scoring of PR-positive tumor cells, but not ER-positive tumor
cells, might help identify good-outcome breast cancers. To test this
hypothesis, we evaluated the association of the visually determined
percentage of PR-positive and ER-positive invasive breast carcinoma
cells with survival outcomes within IHC-luminal A tumors of the BCCA-
tamoxifen cohort.6 As expected, the percentage of PR-positive cancer
cells, but not the percentage of ER-positive cancer cells (data not shown),
was associated with DRFS after adjusting for standard clinicopathologic
variables,withtheoptimalPRpercentagecutoff topredictoutcomebeing
found to be 20% (Appendix Fig A2-A3, online only). In contrast, within
IHC-luminal B/HER2-negative tumors (ie, HR-positive/Ki-67  14%),
semiquantitative expression of either PR or ER was not found to be
associated with outcome differences (data not shown).
We then tested the prognostic value of the PR cutoff of more than
20% within IHC-luminal A tumors in two independent cohorts of
patients with primary breast cancer (GEICAM 990611 and the
BCCA-no AST cohorts9). In both data sets, patients with IHC-luminal
A tumors having low positive PR-positive tumor cells ( 20%)
showed significantly poorer survival compared with tumors with
more than 20% of PR-positive tumor cells (Figs 2A and 2B).
Multivariable analyses confirmed the independent association
between PR expression and survival (Appendix Table A4-A5, online








Luminal A Luminal B
P
Luminal A Luminal B
P
Luminal A Luminal B
PNo. % No. % No. % No. % No. % No. %
No. 372 329 — 278 264 — 594 414 —
Mean age, years 66.6 67.4  .05 50.8 51.7  .05 53.5 55.2 .03
Grade
1 25 7 5 2  .001 69 25 26 10  .001 173 82 38 18  .001
2 186 54 129 41 141 51 112 42 272 64 152 36
3 135 39 179 57 68 10 126 47 96 35 176 65
Nodal positivity 245 72.1 215 69  .05 — — — 220 38 195 49 .002
Tumor size  2.0 cm 150 44 165 56 .003 136 49 166 63 .0031 341 57 280 68 .001
IHC ER-positive status — — — 257 93 240 92  .05 552 94 390 95 .583
IHC PR-positive status 248 72 174 56  .001 261 94 195 74  .001 206 80 99 66 .001
Clinical HER2-positive status 15 4 30 9 .0067 4 2 37 14  .001 14 6 19 14 .008
Abbreviations: BCCA, British Columbia Cancer Agency; ER, estrogen receptor; GEICAM, Grupo Español de Investigación en Cáncer de Mama;
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.







HER2 Positive % HER2 Positive % Triple Negative %
BCCA-tamoxifen
Luminal A 286 81.5 50 14.2 15 4.3 — — — —
Luminal B 109 35.4 169 54.9 30 9.7 — — — —
GEICAM 9906
Luminal A 231 85.2 32 11.8 4 1.5 0 0 4 1.5
Luminal B 134 51.9 77 29.8 30 11.6 7 2.7 10 3.9
NOTE. Within hormone receptor–positive/HER2-negative disease, the concordance  value score between the PAM50 luminal A and B definition with the
IHC-luminal A and IHC-luminal B/HER2-negative definitions was 0.196 and 0.407 (slight to fair agreement) in the GEICAM 9906 cohorts11 and
BCCA-tamoxifen,6 respectively.
Abbreviations: BCCA, British Columbia Cancer Agency; GEICAM, Grupo Español de Investigación en Cáncer de Mama; HER2, human epidermal growth factor
receptor 2; IHC, immunohistochemistry.
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only). In the BCCA-no AST cohort, the breast cancer–specific survival
at 15 years of patients with IHC-luminal A tumors with more than
20% PR-positive tumor cells was 94.0% (95% CI, 91.6% to 98.2%).
We next evaluated the distribution of the gene-expression based
intrinsic subtypes (gold standard) within IHC-luminal A tumors in the
GEICAM 9906 cohort based on this more than 20% PR cutoff (Table 3).
Consistent with the preceding findings, 63% of IHC-luminal A tumors
with more than 20% of PR-positive cells were identified as luminal A,
whereas 24% of IHC-luminal A tumors with  20% of PR-positive cells
were identified as luminal A, thus confirming that this definition helps to
better discriminate true luminal A tumors from the rest. Finally, although
the PR cutoff of 20% increased the percentage of luminal A tumors
identified within what would otherwise have been considered IHC-
luminal B/HER2-negative tumors from 5.9% to 30.9%, the majority of
this group remained composed of luminal B (55.6%) tumors.
Comparison of Prognostic Values of IHC-Based
Subtypes, IHC4 Score, and PAM50-ROR-P Score
We compared the contribution of the newly proposed IHC-
based subtype definitions (IHC-luminal A [HR positive/HER2 nega-
tive/Ki-67  14%/PR  20%] and IHC-luminal B [HR positive/
HER2 negative/Ki-67  14%/PR  20% or HR positive/HER2
negative/Ki-67  14%]) with a version of the IHC4 score8 and with
PAM50 ROR-P score6 in the subset of patients with HR-positive/
HER2-negative tumors from the GEICAM 9906 cohort11 (n  580).
All three classifications added significant prognostic information be-
yond clinical variables (Figs 3A, 3B, and 3C), with IHC-based subtypes
and IHC4 score providing similar amounts of prognostic information
and PAM50 ROR-P providing the largest amount.
Finally, we evaluated the independent prognostic information
that each classification provided when considered in the presence of
one of the others. When the IHC4 score was included in the model,
adding intrinsic IHC-based subtype did not provide significant inde-
pendent information (Fig 3D). However, when the IHC-based sub-
type was included in the model, the IHC4 score did not provide
additional information (Fig 3E). On the other hand, inclusion of
PAM50 ROR-P provided significant independent prognostic infor-
mation beyond the information provided by either the IHC4 score or
the IHC-based subtypes (Figs 3D and 3E).
DISCUSSION
Patients with early breast cancer with tumors that are ER positive













































2 4 6 8 10
Log-rank P = .0057
PR ≤ 20%
PR > 20%












Fig 2. Kaplan-Meier survival analysis within immunohistochemical-based luminal A tumors (hormone receptor positive/HER2 negative/Ki-67  14%) based on the
percentage of progesterone receptor (PR) –positive tumor cells. (A) Grupo Español de Investigación en Cáncer de Mama 9906 cohort. (B) British Columbia Cancer
Agency–no adjuvant systemic therapy cohort.
Table 3. Distribution of the PAM50 Subtypes Across the Luminal A and B IHC-Based Subtypes in GEICAM 9906
Subtype and PR Status
PAM50 Subtypes
Luminal A % Luminal B % HER2 Enriched % Basal-Like % Normal-Like % Total
IHC-luminal A 231 52.3 134 30.3 56 12.7 3 0.7 18 4.1 442
PR  20% 27 22.7 61 51.3 24 20.2 3 2.5 4 3.4 119
PR  20% 204 63.2 73 22.6 32 9.9 0 0 14 4.3 323
IHC-luminal B/HER2 negative 28 21.2 77 58.3 19 14.4 8 6.1 0 0.0 132
PR  20% 3 5.9 32 62.7 10 19.6 6 11.8 0 0.0 51
PR  20% 25 30.9 45 55.6 9 11.1 2 2.5 0 0.0 81
IHC-luminal B/HER2 positive 4 5.6 30 41.7 38 52.8 0 0.0 0 0.0 72
PR  20% 0 0.0 13 33.3 26 66.7 0 0.0 0 0.0 39
PR  20% 4 12.1 17 51.5 12 36.4 0 0.0 0 0.0 33
Abbreviations: GEICAM, Grupo Español de Investigación en Cáncer de Mama; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR,
progesterone receptor.
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mortality compared with women with ER-negative and/or PR-
negative disease.3,15 However, few studies have evaluated variations in
these risks across ER/PR status.15-18 In Dunnwald et al,16 women with
ER-positive/PR-negative, ER-negative/PR-positive, or ER-negative/
PR-negative tumors experienced higher risks of mortality compared
with women with ER-positive/PR-positive tumors, independent of
the various demographic and clinical tumor characteristics. These
data are concordant with our centrally reviewed pathology data pre-
sented here, which show that PR positivity, and especially high expres-
sion of PR protein, is more frequently observed in tumors with a better
baseline prognosis (ie, luminal A) than tumors with a poor baseline
prognosis (ie, luminal B). It is important to note that a substantial
number of luminal B tumors (50% to 75%) are still PR positive,
although the expression of PR may be less than in luminal A tumors.
The ability of ER and/or PR expression to predict benefit to
endocrine and/or cytotoxic therapy has also been evaluated. In terms
of endocrine sensitivity, a recent patient-level meta-analysis of ran-
domized trials from the Early Breast Cancer Trialists’ Collaborative
Group that evaluated adjuvant tamoxifen versus no adjuvant tamox-
ifen suggested that recurrence and death rate ratio is independent of
PR status (or level) in ER-positive disease.19 Similar data have been
observed in another smaller randomized adjuvant study.20 In addi-
tion, PR expression levels have not shown to predict aromatase inhib-
itor efficacy over tamoxifen in ER-expressing tumors in two large
adjuvant clinical trials.21,22 This is concordant with a recent neoadju-
vant trial in which luminal A and B tumors, as defined by the PAM50
assay, did not show significant differences in terms of response to
aromatase inhibitors, although luminal A tumors achieved higher
rates of Preoperative Endocrine Prognostic Index score of 0, which is a
validated biomarker of outstanding outcome after adjuvant endocrine
therapy alone.23 Overall, these data suggest that luminal A and B
tumors benefit similarly from endocrine therapies, but that patients
with luminal A tumors have a better baseline prognosis than those
with luminal B tumors.
In terms of chemotherapy benefit, the majority of adjuvant and
neoadjuvant data suggest that HR status is a strong predictor of gen-
eral chemosensitivity, with HR-positive tumors showing less benefit
to cytotoxic drugs than HR-negative tumors. Moreover, in the neoad-
juvant setting, luminal A tumors achieve lower rates of pathologic
complete response with anthracycline/taxane-based chemotherapy
compared with luminal B tumors.24 In addition, Oncotype DX has
shown that within HR-positive disease, those tumors with high RS (ie,
non–luminal A tumors) benefit the most from adjuvant chemother-
apy.25,26 Interestingly, in a retrospective analysis from three adjuvant
clinical trials, low expression of both ER and PR, and potentially low
expression of PR within ER-positive patients, was found predictive of
adding chemotherapy to endocrine therapy.27 Overall, these data sug-
gest that luminal A tumors are less chemosensitive than luminal Bs.
A critical issue in HR-positive disease is the identification of
patients who can be considered virtually cured with endocrine therapy
alone and so do not need adjuvant systemic chemotherapy.4,6 Gene
expression–based assays such as the PAM50 ROR and Oncotype DX
RS can help identify these groups of patients, especially within node-
negative disease.28 Recently, a combined semiquantitative IHC-based
scoring of ER, PR, HER2, and Ki-67, known as IHC4 score, has shown
to provide similar prognostic information as is provided by Oncotype
DX RS.8 In this report, we have shown that a version of the IHC4 score
is significantly associated with outcome, but did not add significant
prognostic information once our newly improved intrinsic IHC-
based subtypes were known within HR-positive/HER2-negative dis-
ease. This is probably due to the fact that both pathology-based
determinations are using the same four biomarkers to identify similar
prognostic groups.
There are several issues that need to be considered in this study.
First, the information provided by IHC-based biomarkers cannot
simply be used to substitute the information coming from multigene-
based assays, and even in the presence of IHC-based assays, the gene
expression ROR assay was a strong prognostic feature. However, as
stated previously, multigene expression-based assays are not globally
available, and in their absence, well-designed IHC assays are valuable
for baseline prognostic estimations. A second issue is that many genes
were found differentially expressed when luminal A tumors were
compared with luminal B tumors, and the quantitative IHC expres-
sion of some of these biomarkers could have potentially performed
better than PR. However, we decided to focus on the expression of PR
because this biomarker is widely used in the community and is already
part of the standard assessment at most institutions. Third, the IHC-
based subtype definitions evaluated here were performed in a central-
ized laboratory under a single protocol, and one antibody per protein/
target, which may not reflect the everyday performance of these tests in
the clinical setting, where multiple laboratories with different antibod-
ies is more likely to be the approach. Fourth, the IHC4 score evaluated
in our study is slightly different from that of Cuzik et al8 as a result of
the use of different antibodies for ER and PR and the use of a general
intensity score of ER-positive tumor cells. Nonetheless, the association
of the IHC4 score with survival was found to be strong, as previ-
ously reported.8
To conclude, IHC subtype–based definitions of genomically de-
fined luminal A and B tumors are imperfect because of the nature and
limitations of pathology-based tests. However, semiquantitative mea-
surement of the percentage of PR-positive cells within HR-positive/
HER2-negative/Ki-67 less than 14% tumors helps to identify patients
who may be considered most effectively treated with endocrine






































Fig 3. Disease-free survival log likelihood ratio (LR) statistics of six different
predictive models (A–E) in patients of the Grupo Español de Investigación en
Cáncer de Mama 9906 cohort with hormone receptor (HR) –positive/human
epidermal growth factor receptor 2 (HER2) --negative breast cancer. The vari-
ables evaluated were the following: immunohistochemical (IHC)-based scoring of
estrogen receptor, progesterone receptor, HER2, and Ki-67 (IHC4 score; contin-
uous variable), IHC-based subtypes (HR positive/HER2 negative/Ki-67  14%
 20% [luminal A], HR positive/HER2 negative/Ki-67  14%  20% and HR
positive/HER2 negative/Ki-67  14% [luminal B]), and PAM50 risk of recurrence
score based on subtype and proliferation (ROR-P; continuous variable). (*) P  .05.
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luminal A tumors is HR-positive/HER2-negative/Ki-67 less than 14%
and PR more than 20%.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Although all authors completed the disclosure declaration, the following
author(s) and/or an author’s immediate family member(s) indicated a
financial or other interest that is relevant to the subject matter under
consideration in this article. Certain relationships marked with a “U” are
those for which no compensation was received; those relationships marked
with a “C” were compensated. For a detailed description of the disclosure
categories, or for more information about ASCO’s conflict of interest policy,
please refer to the Author Disclosure Declaration and the Disclosures of
Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: None Consultant or Advisory
Role: Torsten O. Nielsen, BioClassifier (C) Stock Ownership: Philip S.
Bernard, University Genomics, BioClassifier; Charles M. Perou,
University Genomics, BioClassifier Honoraria: None Research Funding:
None Expert Testimony: None Other Remuneration: None
AUTHOR CONTRIBUTIONS
Conception and design: Aleix Prat, Charles M. Perou
Administrative support: Rosalía Caballero
Provision of study materials or patients: Maggie Chon U. Cheang,
Miguel Martín, Eva Carrasco, Rosalía Caballero, Philip S. Bernard,
Torsten O. Nielsen, Charles M. Perou
Collection and assembly of data: Aleix Prat, Maggie Chon U. Cheang,
Miguel Martín, Eva Carrasco, Rosalía Caballero, Philip S. Bernard,
Charles M. Perou
Data analysis and interpretation: Aleix Prat, Maggie Chon U. Cheang,
Miguel Martín, Joel S. Parker, Scott Tyldesley, Karen Gelmon, Philip S.
Bernard, Torsten O. Nielsen, Charles M. Perou
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Prat A, Perou CM: Deconstructing the molecu-
lar portraits of breast cancer. Mol Oncol 5:5-23, 2011
2. Oh DS, Troester MA, Usary J, et al: Estrogen-
regulated genes predict survival in hormone receptor-
positive breast cancers. J Clin Oncol 24:1656-1664, 2006
3. Perou CM, Sørlie T, Eisen MB, et al: Molecu-
lar portraits of human breast tumours. Nature 406:
747-752, 2000
4. Prat A, Ellis MJ, Perou CM: Practical implica-
tions of gene-expression-based assays for breast
oncologists. Nat Rev Clin Oncol 9:48-57, 2012
5. Parker JS, Mullins M, Cheang MC, et al:
Supervised risk predictor of breast cancer based on
intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
6. Nielsen TO, Parker JS, Leung S, et al: A
comparison of PAM50 intrinsic subtyping with im-
munohistochemistry and clinical prognostic factors
in tamoxifen-treated estrogen receptor-positive
breast cancer. Clin Cancer Res 16:5222-5232, 2010
7. Allison KH, Kandalaft PL, Sitlani CM, et al:
Routine pathologic parameters can predict On-
cotype DX(TM) recurrence scores in subsets of ER
positive patients: Who does not always need test-
ing? Breast Cancer Res Treat 131:413-424, 2012
8. Cuzick J, Dowsett M, Pineda S, et al: Prog-
nostic value of a combined estrogen receptor, pro-
gesterone receptor, Ki-67, and human epidermal
growth factor receptor 2 immunohistochemical
score and comparison with the Genomic Health
recurrence score in early breast cancer. J Clin Oncol
29:4273-4278, 2011
9. Cheang MC, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with
luminal B breast cancer. J Natl Cancer Inst 101:736-
750, 2009
10. Goldhirsch A, Wood WC, Coates AS, et al:
Strategies for subtypes–dealing with the diversity of
breast cancer: Highlights of the St. Gallen Interna-
tional Expert Consensus on the Primary Therapy of
Early Breast Cancer 2011. Ann Oncol 22:1736-1747,
2011
11. Martín M, Rodríguez-Lescure A, Ruiz A, et al:
Randomized phase 3 trial of fluorouracil, epirubicin,
and cyclophosphamide alone or followed by pacli-
taxel for early breast cancer. J Natl Cancer Inst
100:805-814, 2008
12. Martín M, Rodríguez-Lescure A, Ruiz A, et al:
Molecular predictors of efficacy of adjuvant weekly
paclitaxel in early breast cancer. Breast Cancer Res
Treat 123:149-157, 2010
13. Genetic Pathology Evaluation Centre: TMA
viewer. http://www.gpecimage.ubc.ca/
14. Huang DW, Sherman BT, Lempicki RA: Sys-
tematic and integrative analysis of large gene lists
using DAVID bioinformatics resources. Nat Proto-
cols 4:44-57, 2009
15. Bauer K, Parise C, Caggiano V: Use of ER/PR/
HER2 subtypes in conjunction with the 2007 St
Gallen Consensus Statement for early breast can-
cer. BMC Cancer 10:228, 2010
16. Dunnwald L, Rossing M, Li C: Hormone re-
ceptor status, tumor characteristics, and prognosis:
a prospective cohort of breast cancer patients.
Breast Cancer Res 9:R6, 2007
17. Grann VR, Troxel AB, Zojwalla NJ, et al: Hor-
mone receptor status and survival in a population-
based cohort of patients with breast carcinoma.
Cancer 103:2241-2251, 2005
18. Mohsin SK, Weiss H, Havighurst T, et al:
Progesterone receptor by immunohistochemistry
and clinical outcome in breast cancer: A validation
study. Mod Pathol 17:1545-1554, 2004
19. Early Breast Cancer Trialists’ Collaborative
Group (EGCTCG), Davies C, Godwin J, et al: Rele-
vance of breast cancer hormone receptors and other
factors to the efficacy of adjuvant tamoxifen:
Patient-level meta-analysis of randomised trials.
Lancet 378:771-784, 2011
20. Dowsett M, Houghton J, Iden C, et al: Benefit
from adjuvant tamoxifen therapy in primary breast
cancer patients according oestrogen receptor, pro-
gesterone receptor, EGF receptor and HER2 status.
Ann Oncol 17:818-826, 2006
21. Viale G, Regan MM, Maiorano E, et al: Prognos-
tic and predictive value of centrally reviewed expres-
sion of estrogen and progesterone receptors in a
randomized trial comparing letrozole and tamoxifen
adjuvant therapy for postmenopausal early breast can-
cer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
22. Dowsett M, Allred C, Knox J, et al: Relation-
ship between quantitative estrogen and progester-
one receptor expression and human epidermal
growth factor receptor 2 (HER-2) status with recur-
rence in the Arimidex, Tamoxifen, Alone or in Com-
bination Trial. J Clin Oncol 26:1059-1065, 2008
23. Ellis MJ, Suman VJ, Hoog J, et al: ACOSOG
Z1031, a randomized phase 2 neoadjuvant compar-
ison between letrozole, anastrozole and exemes-
tane for postmenopausal women with ER rich stage
2/3 breast cancer: Clinical and biomarker outcomes
and the predictive value of the baseline PAM50-
based intrinsic subtype—ACOSOG Z1031. J Clin
Oncol 29:2342-2349, 2011
24. Parker J, Prat A, Cheang M, et al: Breast cancer
molecular subtypes predict response to anthracycline/
taxane-based chemotherapy. Presented at the San
Antonio Breast Cancer Symposium, San Antonio, TX,
December 9-13, 2009 (abstr 2019)
25. Albain KS, Barlow WE, Shak S, et al: Prognos-
tic and predictive value of the 21-gene recurrence
score assay in postmenopausal women with node-
positive, oestrogen-receptor-positive breast cancer
on chemotherapy: A retrospective analysis of a
randomised trial. Lancet Oncol 11:55-65, 2010
26. Paik S, Tang G, Shak S, et al: Gene expression
and benefit of chemotherapy in women with node
negative, estrogen receptor positive breast cancer.
J Clin Oncol 24:3726-3734, 2006
27. Viale G, Regan MM, Maiorano E, et al: Che-
moendocrine compared with endocrine adjuvant ther-
apies for node-negative breast cancer: Predictive value
of centrally reviewed expression of estrogen and pro-
gesterone receptors—An International Breast Cancer
Study Group. J Clin Oncol 26:1404-1410, 2008
28. Prat A, Parker J, Fan C, et al: Concordance
among gene-expression-based predictors for ER-
positive breast cancer treated with adjuvant tamox-
ifen. Ann Oncol [epub ahead of print on April 24, 2012]
■ ■ ■
Prognostic Significance of PR-Positive Breast Tumor Cells
www.jco.org © 2012 by American Society of Clinical Oncology 209
